Market research
QSAM Qsam Biosciences Inc
OTCQB USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 37M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.81
Profile
Company facts
- Exchange
- OTCQB
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US74738N1037
- Market cap
- 37M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.81
About
About Qsam Biosciences Inc
QSAM Biosciences, Inc. engages in developing various nuclear medicines for the treatment of cancer. The company is involved in the development of CycloSam (Samaium-153 DOTMP), a clinical-stage bone targeting radiopharmaceutical. It has a license agreement with IGL Pharma, Inc. The company was formerly known as Q2Earth, Inc. and changed its name to QSAM Biosciences, Inc. in September 2020. QSAM Biosciences, Inc. was incorporated in 2004 and is headquartered in Austin, Texas. As of May 3, 2024, QSAM Biosciences, Inc. operates as a subsidiary of Telix Pharmaceuticals (Us) Inc.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the QSAM discussion.
No comments yet
Start a focused discussion about QSAM.